Skip to main content
SpringerLink
Log in
Book cover

Anticancer Drug Development Guide

Preclinical Screening, Clinical Trials, and Approval

  • Book
  • © 2004

Overview

Editors:
  1. Beverly A. Teicher

    1. Oncology Discovery and Research, Genzyme Corporation, Framingham, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Paul A. Andrews

    1. Preclinical Sciences, Aton Pharma Inc., Tarrytown, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (23 chapters)

  1. Front Matter

    Pages i-xiv
    Download chapter PDF

  2. In Vitro Methods

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. High-Volume Screening

      • Michel Pagé
      Pages 3-21

    3. High-Throughput Screening in Industry

      • Michael D. Boisclair, David A. Egan, Kety Huberman, Ralph Infantino
      Pages 23-39

    4. The NCI Human Tumor Cell Line (60-Cell) Screen

      • Michael R. Boyd
      Pages 41-61

    5. Human Tumor Screening

      • Axel-R. Hanauske, Susan G. Hilsenbeck, Daniel D. Von Hoff
      Pages 63-76

  3. In Vivo Methods

    1. Front Matter

      Pages 77-77
      Download chapter PDF

    2. Murine L1210 and P388 Leukemias

      • William R. Waud
      Pages 79-97

    3. In Vivo Methods for Screening and Preclinical Testing

      • Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh et al.
      Pages 99-123

    4. Human Tumor Xenograft Models in NCI Drug Development

      • Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes, William R. Waud
      Pages 125-152

    5. NCI Specialized Procedures in Preclinical Drug Evaluations

      • Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox, Sherman F. Stinson
      Pages 153-182

    6. Patient-Like Orthotopic Metastatic Models of Human Cancer

      • Robert M. Hoffman
      Pages 183-212

    7. Preclinical Models for Combination Therapy

      • Beverly A. Teicher
      Pages 213-242

    8. Models for Biomarkers and Minimal Residual Tumor

      • Beverly A. Teicher
      Pages 243-258

    9. Spontaneously Occurring Tumors in Companion Animals as Models for Drug Development

      • David M. Vail, Douglas H. Thamm
      Pages 259-284

  4. Nonclinical Testing to Support Human Trials

    1. Front Matter

      Pages 285-285
      Download chapter PDF

    2. Nonclinical Testing

      • Denis Roy, Paul A. Andrews
      Pages 287-311

    3. Nonclinical Testing for Oncology Drug Products

      • Paul A. Andrews, Denis Roy
      Pages 313-323

    4. Nonclinical Testing for Oncology Biologic Products

      • Carolyn M. Laurençot, Denis Roy, Paul A. Andrews
      Pages 325-335

  5. Clinical Testing

    1. Front Matter

      Pages 337-337
      Download chapter PDF
Back to top

Keywords

About this book

This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.

Reviews

From Reviews of the First Edition:

"...traces the critically important pathway by which a 'molecule' becomes an 'an anticancer agent'."
-Unlisted Drugs

"...this book is a must for all oncology fellows and junior faculty interested in drug development and will be a welcome addition on the bookshelf of all oncologists, pharmacists and other professionals interested in understanding this complex area." -Journal of Clinical Oncology

Editors and Affiliations

  • Oncology Discovery and Research, Genzyme Corporation, Framingham, USA

    Beverly A. Teicher

  • Preclinical Sciences, Aton Pharma Inc., Tarrytown, USA

    Paul A. Andrews

Bibliographic Information

  • Book Title: Anticancer Drug Development Guide

  • Book Subtitle: Preclinical Screening, Clinical Trials, and Approval

  • Editors: Beverly A. Teicher, Paul A. Andrews

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-59259-739-0

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2004

  • Hardcover ISBN: 978-1-58829-228-5Published: 01 February 2004

  • Softcover ISBN: 978-1-4684-9841-7Published: 08 August 2012

  • eBook ISBN: 978-1-59259-739-0Published: 01 February 2004

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XIV, 451

  • Number of Illustrations: 161 b/w illustrations

  • Topics: Oncology, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation